Illustration: Radina Dobrinova for Endpoints News

Once a sci­en­tif­ic back­wa­ter, pro­tein re­search at­tracts bil­lion-dol­lar deals and high-pro­file pub­li­ca­tions

When it comes to de­tect­ing dis­ease and un­der­stand­ing how the body works, pro­tein re­search has long been over­shad­owed by DNA se­quenc­ing.

But the field, known as pro­teomics, has seen a surge of ac­tiv­i­ty in re­cent months. Larg­er play­ers have struck bil­lion-dol­lar-plus deals, a pro­posed $1.4 bil­lion in­ter­na­tion­al col­lab­o­ra­tion has launched, and new re­search has shown that a pro­teomics can­cer di­ag­nos­tic might chal­lenge some of the DNA-based play­ers that cur­rent­ly dom­i­nate that field.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.